Humana Inc HUM reported Q1 adjusted EPS of $9.38, up from $7.81 a year ago, beating the consensus of $9.27.
Humana said in a statement that its first-quarter 2023 performance was underpinned by robust membership growth and favorable inpatient utilization trends in the individual Medicare Advantage (MA) business.
The insurer reported revenue of $26.74 billion in the first quarter of 2023, up 12% from $23.9 billion a year ago, below the consensus of $26.44 billion.
Humana ended the quarter with 17.1 million members across all of its plans, including 8.6 million across its MA and standalone Medicare prescription drug plans.
Related: Bargain Hunters, Rejoice: Analyst Unveils Undervalued Humana Stock, Kicks Off Coverage.
Guidance: Humana forecasts adjusted EPS of at least $28.25, up from $28 expected earlier versus the consensus Of $28.11 on the strength of Q1 results.
"All in, we are pleased with the solid start, which reflects our company's strong fundamentals and positions us well for meeting our mid-term Adjusted EPS target of $37 in 2025," said Bruce Broussard, Humana's president & CEO.
The insurer projected strong individual MA membership growth for 2023, and it expects to add 775,000 MA members this year, or growth of 17% from 2022, "meaningfully higher than industry growth."
Price Action: HUM shares are up 0.12% at $502.27 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.